Tenaya Therapeutics Inc(TNYA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:55 PM ET (Korea 10/31 08:55)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.53 | Insider Own | 1.34% | Shs Outstand | 227.9M | Perf Week | -5.55% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | 23.75% | Insider Trans | -1.22% | Shs Float | 224.9M | Perf Month | -35.05% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.1 | Inst Own | 25.24% | Short Float | 10.01% | Perf Quarter | -49.6% |
| Income | -0.10B | P/S | 62.97 | EPS this Y | 18.64% | Inst Trans | -0.73% | Short Ratio | 8.17 | Perf Half Y | -47.95% |
| Sales | 0.00B | P/B | 1.19 | EPS next 5Y | - | ROA | -95.61% | Short Interest | 22.52M | Perf YTD | -48.36% |
| Book/sh | 0.31 | P/C | 1.07 | EPS past 3/5Y | 40.12% 8.63% | ROE | -121.86% | 52W High | -76.45% ($1.56) | Perf Year | -70.84% |
| Cash/sh | 0.34 | P/FCF | - | Sales past 3/5Y | - | ROIC | -146.31% | 52W Low | 2.03% ($0.36) | Perf 3Y | -78.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 45.08% | Gross Margin | -435.73% | Volatility(W/M) | 6.21% 8.76% | Perf 5Y | -98.57% |
| Dividend TTM | - | EV/Sales | 7.23 | Sales Y/Y TTM | - | Oper. Margin | -6192.88% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.52 | EPS Q/Q | -39.44% | Profit Margin | -7723.97% | RSI (14) | 27.78 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.52 | Sales Q/Q | - | SMA20 | -18.07% ($0.45) | Beta | 2.83 | Target Price | $9.33 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/5 | SMA50 | -36.05% ($0.58) | Rel Volume | 0.95 | Prev Close | $0.4 |
| Employees | 70 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -192.83% -88.92% | SMA200 | -48.29% ($0.72) | Avg Volume(3M) | 2.76M | Price | $0.37 |
| IPO | 2021/7/30 | Option/Short | Yes/Yes | Trades | 2381 | Volume | 2,611,791 | Change | -7.78% |
Tenaya Therapeutics (TNYA) is a clinical-stage biotechnology company headquartered in California, USA, listed on the Nasdaq. The company focuses on developing AAV vector-based gene therapies targeting inherited heart diseases, with a pipeline aimed at MYBPC3-related hypertrophic cardiomyopathy and PKP2-related arrhythmogenic cardiomyopathy. As a clinical-stage biotech with no commercial revenue yet, clinical data readouts and capital-raising activities are the key drivers of share-price volatility.
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
TNYA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +18.6% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $6,297. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 25.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #373 of 595 in the industry
Based on market cap of $84M.
COYA#371 Coya Therapeutics Inc $85M PER - 
RLYB#372 Rallybio Corp $85M PER 3.5 TNYA#373 Tenaya Therapeutics Inc $84M PER - 
RANI#374 Rani Therapeutics Holdings Inc $82M PER - 
CRBP#375 Corbus Pharmaceuticals Holdings Inc $82M PER - 
FAQ
What kind of company is TNYA?
TNYA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TNYA?
The market cap of TNYA is approximately $84M, ranking 4,557 within its sector.
What is the 52-week high and low for TNYA?
TNYA has recorded a 52-week high of $1.56 and a low of $0.36.
